HC Wainwright & Co. Maintains Buy on Ventyx Biosciences, Lowers Price Target to $52
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $54 to $52.

August 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target, Ventyx Biosciences maintains a 'Buy' rating from HC Wainwright & Co.
The lowered price target might indicate a slightly less optimistic outlook for Ventyx Biosciences. However, the maintained 'Buy' rating suggests that HC Wainwright & Co. still sees potential in the company's stock, which could balance out any negative impact from the price target adjustment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100